Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 5544

Original article / research
Year : 2017 | Month : March | Volume : 11 | Issue : 3 | Page : WC06 - WC09

Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria

Vippan Goyal, Anu Gupta, Onam Gupta, Dhruvendra Lal, Manharan Gill

1. Associate Professor and Head, Department of Dermatology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India. 2. Assistant Professor, Department of Dermatology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India. 3. Intern, Department of Dermatology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India. 4. Post Graduate Student, Department of Community Medicine, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India. 5. Senior Resident, Department of Dermatology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India.

Correspondence Address :
Dr. Vippan Goyal,
House No. 204, Patel Nagar, Bathinda, Punjab-151001, India.
E-mail: vippangoyal@rediffmail.com

Abstract

Introduction: Acute and chronic urticaria can result in severely impaired quality of life from pruritus and associated sleep lessness, as well as anxiety and depression. Various treatment modalities are available out of which second generation non sedating H1 antihistamines e.g., fexofenadine, loratidine, desloratadine, cetirizine, levocetirizine, ebastine etc., are used as the first line treatment.

Aim: To compare the safety and efficacy of ebastine 20 mg, ebastine 10 mg and levocetirizine 5 mg in the patients of urticaria

Materials and Methods: A longitudinal study was conducted in dermatology Outpatient Department (OPD) of Adesh Institute of Medical Sciences and Research, Bathinda, India. A total of 150 patients between the age group 10-70 years, both men and women having urticaria were enrolled and divided into three groups of 50 each. Group A was given ebastine 20 mg OD, Group B was given ebastine 10 mg OD and Group C was given levocetirizine 5 mg OD. The patients were asked to scale their severity of disease over a period of follow up based on Urticarial Activity Score 7 (Uas 7).

Results: The mean age of patients was 32.82 years. The mean UAS 7 score at the end of 4th week was 1.08 with ebastine 20 mg, 1.98 with levocetirizine 5 mg and 3.98 with ebastine 10 mg. In group A, 40 out of 50 patients (i.e., 80%), in Group B 25 out of 50 (i.e., 50%) get UAS7=0 and in Group C, 35 (i.e., 70%) patients who got relieved of symptoms at the end of treatment. When the scores were redefined and categorized under relieved and not relieved, and comparison done between all three groups, then there was a significant difference in the number of patients getting relieved, with p<0.001 (highly significant). Levocetirizine 5 mg had shown more side effects like dryness of mouth and sedation as compare to ebastine irrespective of dosage. The comparison made between the number of patients developing side effects among the groups was highly significant (p<0.001) for all the side effects.

Conclusion: Ebastine 20 mg is found to have superior efficacy for treatment of Urticaria as compared to ebastine 10 mg but with levocetirizine 5 mg the results were almost similar. Tolerability of ebastine 20 mg is similar to ebastine 10 mg but with levocetirizine 5 mg there were more side effects and less tolerability.

Keywords

Antihistamines, Darrier sign, Tolerability

How to cite this article :

Vippan Goyal, Anu Gupta, Onam Gupta, Dhruvendra Lal, Manharan Gill. COMPARATIVE EFFICACY AND SAFETY OF EBASTINE 20 MG, EBASTINE 10 MG AND LEVOCETIRIZINE 5 MG IN ACUTE URTICARIA. Journal of Clinical and Diagnostic Research [serial online] 2017 March [cited: 2017 Mar 27 ]; 11:WC06-WC09. Available from
http://jcdr.net/back_issues.asp?issn=0973-709x&year=2017&month=March&volume=11&issue=3&page=WC06-WC09&id=9550

DOI and Others

DOI: 10.7860/JCDR/2017/23961.9550


Date of Submission: Sep 06, 2016
Date of Peer Review: Oct 11, 2016
Date of Acceptance: Nov 17, 2016
Date of Publishing: Mar 01, 2017


Financial OR OTHER COMPETING INTERESTS: None.

JCDR is now Monthly and more widely Indexed .
  • PubMed Central® (PMC)New
  • Academic Search Complete Database
  • Chemical Abstracts Service
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhostNew
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Open J-Gate
  • Popline (reproductive health literature)
  • SCOPUS
  • www.omnimedicalsearch.com